Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Lung Cancers / Small Cell Lung Cancer
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: May 8, 2013
Question
My Mom was diagnosed with small cell lung cancer in January. They found some spots around her aorta, in her lymph nodes, and in the spine. She is just completing her 4th cycle of chemotherapy. The doctor said now we stop treatment and watch and wait. My question is, what are the chances of recurrence? We were told that there is a 50% mortality rate in 9 months, and 90% mortality in 2 years. Statistically speaking, does that mean it will take a turn for the worse in the next few months, and most likely she will die in the next 1-2 years?
Answer
Barbara Campling, MD, Medical Oncologist, responds:
From what you say, it sounds like your mother has "extensive-stage" small cell lung cancer, which means that the cancer had spread outside of the chest at the time of diagnosis. Chemotherapy is generally quite effective at treating this in the short term. The goals of treatment for extensive-stage small cell lung cancer are to shrink the tumor, relieve symptoms, and improve survival, all of which chemotherapy can do. Unfortunately, once the cancer has spread outside of the chest, the cancer cannot be eradicated. She is now completing her planned chemotherapy, and you are now wondering what the future holds for her, and how long she has to live.
Because the cancer had already spread outside of the chest at diagnosis, it is almost inevitable that it will start to grow again in the future, regardless of how well she responded to chemotherapy. How long will it be before this happens? That depends, to a certain extent, on how well she has responded to the initial chemotherapy treatment. If she has had a "complete response" to chemotherapy, meaning that the tumor can no longer be detected on any of her imaging scans, then it is likely to remain dormant for longer than if the response was more limited.
You have been told that the expected mortality is 50% at 9 months. This means that in a large group of patients with extensive-stage small cell lung cancer, half of the patients will be still be alive 9 months after diagnosis, whereas the other half will have died. However, these statistics do not tell us whether your mother will be alive 9 months after diagnosis. A Canadian study that included patients with small cell lung cancer (WJ Mackillop and CF Quirt. Measuring the accuracy of prognostic judgements in oncology. Journal of Clinical Epidemiology. 1997;50:21-29.) demonstrated that doctors are very good at predicting which patients would or would not be cured, but we are not very accurate when it comes to predicting how long individual incurable patients would survive. I often hear patients make statements like "my doctor gave me 10 months to live," and I try to avoid making these predictions myself.
If your mother has had a very good response to chemotherapy treatment, it could be many months before the cancer starts to cause problems again. Once she has recovered from the side effects of the chemotherapy, she could get back to feeling well for a period of time. When the cancer does recur, it may respond again to chemotherapy, and this could relieve her symptoms and improve her survival. Unfortunately, this type of cancer nearly always becomes resistant to further chemotherapy. Even when this occurs, there is usually something that can be done to alleviate symptoms and relieve pain.
Ms. Hollis discusses the role of the nurse practitioner in oncology care. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

